Clinical Trial Finder

Inclusion Criteria:

• - Age above 18 years.

• - Male or female.

• - Subjects in study group must have banked AdMSCs at Celltex (already passed communicable disease screen tests for HIV, syphilis and Hepatitis B and C during banking stage) - Must understand and voluntarily sign an Informed Consent for study participation obtained prior to undergoing any study-specific procedures.

• - Must be diagnosed as OA-knees, OA-hips, or OA-shoulders by radiographic criteria and physical examination.

Exclusion Criteria:

• - Participation in another clinical study (with use of another Investigational Medical Product) within 3 months prior to study treatment start.

• - Unwillingness or inability to comply with study procedures.

• - Patients with serious basic diseases that affect survival, including blood diseases, cachexia, active bleeding, severe malnutrition, etc. - Clinically active malignant disease.

• - Previous thrombotic disorder.

• - History of known pulmonary embolism or known secondary anti-phospholipid syndrome.

• - Known or suspected hypersensitivity to any components used to culture the AdMSCs, e.g. BSA and sulfur-containing products (e.g., DMSO) - Major trauma or surgery within 14 days of study treatment start.

• - Mental condition rendering the subject (or the subject's legally acceptable representative[s]) unable to understand the nature, scope and possible consequences of the study.

• - Alcohol, drug, or medication abuse within one year prior to study treatment start.

• - Any condition that, in the Investigator's opinion, is likely to interfere with evaluation of the AdMSC therapy or satisfactory conduct of the study.

• - Irreversible severe end-organ failure, such as heart failure/attack, stroke, liver and renal failure due to other disease conditions.

• - Patients or family history with a hypercoagulable status, such as protein C/protein S deficiency, factor V Leiden, prothrombin gene mutation, dysfibrinogenemia, etc. - History of long-term use of immunosuppressive agents.

• - Organ transplants in the previous 6 months.

- Pregnant, breastfeeding, or desire to become pregnant or unwilling to practice birth control during participation in the study duration, unless surgically sterilized or postmenopausal during the study

Arms

Experimental: Phase 2 Arm 1 - OA Knee

50 subjects receive two doses of 2.0-2.86 x 10^6 cells/kg on days 0 and 6 via intravenous infusion. On day 3, each subject will receive a single dose of 1.0-2.86 x 10^6 cells/kg via intra-articular injection into the injured joint.

Active Comparator: Phase 2 Arm 2 OA Knee

Control group- 50 subjects receive three doses of 2.0-2.86 x 10^6 cells/kg on day 0, 3, and 6 via intravenous infusion

Experimental: Phase 2 Arm 3 - OA Hip

50 subjects receive two doses of 2.0-2.86 x 10^6 cells/kg on days 0 and 6 via intravenous infusion. On day 3, each subject will receive a single dose of 1.0-2.86 x 10^6 cells/kg via intra-articular injection into the injured joint.

Active Comparator: Phase 2 Arm 4 - OA Hip

Control group- 50 subjects receive three doses of 2.0-2.86 x 10^6 cells/kg on day 0, 3, and 6 via intravenous infusion

Experimental: Phase 2 Arm 5 - OA Shoulder

50 subjects receive two doses of 2.0-2.86 x 10^6 cells/kg on days 0 and 6 via intravenous infusion. On day 3, each subject will receive a single dose of 1.0-2.86 x 10^6 cells/kg via intra-articular injection into the injured joint.

Active Comparator: Phase 2 Arm 6 - OA Shoulder

Control group- 50 subjects receive three doses of 2.0-2.86 x 10^6 cells/kg on day 0, 3, and 6 via intravenous infusion

Interventions

Biological: - Celltex- AdMSCs

Autologous adipose-derived stem cells Culture expanded mesenchymal stem cells isolated from a patient's own abdominal fat tissue